Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
South Korea Companies Commercial

Korea Q1 Roundup: Mixed Earnings Amid M&A, Prescription Sales

Boryung Blasts Into Space

  • Analysis

Executive Summary

Large Korean pharma firms’ first-quarter earnings were mostly mixed on a range of diverse factors such as solid prescription sales and impacts from acquisitions, with some even looking to space for new business opportunities.

You may also be interested in...



Korea's New Fast Track Scheme A GIFT For High-Need Drugs

South Korea designates two more global innovative products for support under a new fast track system, in a move set to speed up patient access to novel therapies.

Korean Biotech IPOs Fall In Tough Environment But Brighter Outlook Ahead?

Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.

New Korea Commission Needs Status To Function As Control Tower: Industry

A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.

Table

View full table

Topics

Related Companies

Tags:
South Korea Companies Commercial
Latest Headlines

Chinese RNA Therapy Developers Extend Fundraising Streak Into December

AbbVie Strikes Again By Teeing Up $8.7bn Offer For Cerevel

Pharvaris’s Oral HAE Prevention Data May Threaten BioCryst’s Orladeyo

J&J In Immunology: “We Plan To Lead The Orals Market”

See All
UsernamePublicRestriction

Register

SC148351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By